Sensei Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Sensei Biotherapeutics, Inc. | |||
| Date: | March 30, 2026 | By: | /s/ Christopher W. Gerry |
|---|---|---|---|
| Christopher W. Gerry | |||
| President and General Counsel | |||
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher W. Gerry and Josiah Craver, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Sensei Biotherapeutics, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Christopher W. Gerry | President and General Counsel (Principal Executive Officer) | March 30, 2026 |
| Christopher W. Gerry | ||
| /s/ Josiah Craver | Senior Vice President of Finance (Principal Financial and Accounting Officer) | March 30, 2026 |
| Josiah Craver | ||
| /s/ Bob Holmen | Director | March 30, 2026 |
| Bob Holmen | ||
| /s/ Thomas Ricks | Director | March 30, 2026 |
| Thomas Ricks | ||
| /s/ Kristian Humer | Director | March 30, 2026 |
| Kristian Humer | ||
| /s/ Phillip Donenberg | Director | March 30, 2026 |
| Phillip Donenberg | ||
| /s/ Anand Parikh | Director | March 30, 2026 |
| Anand Parikh | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Common Stock and Stockholders’ Equity for the Years Ended December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.